Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531

Phase 1

Completed

• Conditions: Alzheimer Disease
• Interventions: Drug: SAM-531; Drug: placebo

• Registration Number: NCT00726115
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-07-28
• Study First Submitted QC: 2008-07-30
• Study First Posted: 2008-07-31
• Study Start: 2008-08
• Primary Completion: 2009-02
• Study Completion: 2009-02
• Status Verified: 2009-07
• Last Update Submitted: 2009-07-29
• Last Update Posted: 2009-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	SAM-531	arm placebo
2	placebo	arm drug

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics, routine Lab tests, Vital signs, ECG	29 days